These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33362203)

  • 21. Predictive Value of Conventional Ultrasound and Contrast-Enhanced Ultrasound in Early Recurrence of Hepatocellular Carcinoma after Surgical Resection.
    Wang Y; Liao J; Qi W; Xie L; Li Y
    Ultrasound Med Biol; 2016 May; 42(5):1042-8. PubMed ID: 26803390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Color coded perfusion analysis and microcirculation imaging with contrast enhanced ultrasound (CEUS) for post-interventional success control following thermal ablative techniques of primary and secondary liver malignancies.
    Rennert J; Wiesinger I; Beyer LP; Schicho A; Stroszczynski C; Wiggermann P; Jung EM
    Clin Hemorheol Microcirc; 2019; 73(1):73-83. PubMed ID: 31561352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison between M-score and LR-M in the reporting system of contrast-enhanced ultrasound LI-RADS.
    Chen LD; Ruan SM; Lin Y; Liang JY; Shen SL; Hu HT; Huang Y; Li W; Wang Z; Xie XY; Lu MD; Kuang M; Wang W
    Eur Radiol; 2019 Aug; 29(8):4249-4257. PubMed ID: 30569182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative Parameters of Contrast-Enhanced Ultrasound Predicting the Response to Combined Immune Checkpoint Inhibitor and Anti-angiogenesis Therapies for Unresectable Hepatocellular Carcinoma.
    Zhang Y; Zheng R; Liu M; Zhang X; Sun Y; Shen H; Chen S; Cai H; Guo W; Xie X; Liu B; Huang G
    Ultrasound Med Biol; 2024 Mar; 50(3):352-357. PubMed ID: 38072718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of volume perfusion computed tomography and contrast-enhanced ultrasound for assessment of therapeutic effect of transarterial chemoembolization in patients with hepatocellular carcinoma: a preliminary report.
    Kaufmann S; Schulze M; Spira D; Horger M
    Acta Radiol; 2016 Jan; 57(1):8-12. PubMed ID: 25585848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
    Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
    Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
    [No Abstract]   [Full Text] [Related]  

  • 27. Role of portal vein tumor thrombosis in quantitative perfusion analysis of contrast-enhanced ultrasound of hepatocellular carcinoma.
    Wang Z; Liu G; Lu MD; Xie X; Kuang M; Wang W; Xu Z; Lin M; Chen L
    Ultrasound Med Biol; 2015 May; 41(5):1277-86. PubMed ID: 25623820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study.
    Ippolito D; Querques G; Okolicsanyi S; Franzesi CT; Strazzabosco M; Sironi S
    Eur J Radiol; 2017 May; 90():34-41. PubMed ID: 28583645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Color coded perfusion imaging with contrast enhanced ultrasound (CEUS) for post-interventional success control following trans-arterial chemoembolization (TACE) of hepatocellular carcinoma.
    Rennert J; Wiesinger I; Schicho A; Beyer LP; Wiggermann P; Stroszczynski C; Jung EM
    PLoS One; 2019; 14(6):e0217599. PubMed ID: 31181127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
    Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
    World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
    Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma.
    Palmieri VO; Santovito D; Marano G; Minerva F; Ricci L; D'Alitto F; Angelelli G; Palasciano G
    Radiol Med; 2015 Jul; 120(7):627-33. PubMed ID: 25599661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.
    Huang JY; Li JW; Lu Q; Luo Y; Lin L; Shi YJ; Li T; Liu JB; Lyshchik A
    Radiology; 2020 Feb; 294(2):329-339. PubMed ID: 31793849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
    Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
    J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic Evaluation of Radiotherapy with Contrast-Enhanced Ultrasound in Non-Resectable Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis.
    Li H; Liu J; Chen M; Li H; Long L
    Med Sci Monit; 2018 Nov; 24():8183-8189. PubMed ID: 30426970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of quantitative contrast-enhanced ultrasound in hepatocellular carcinoma recurrence after ablation.
    Gao Y; Zheng DY; Cui Z; Ma Y; Liu YZ; Zhang W
    World J Gastroenterol; 2015 Sep; 21(36):10418-26. PubMed ID: 26420968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VueBox® perfusion analysis of contrast-enhanced ultrasound (CEUS) examinations in patients with primary hyperparathyroidism for preoperative detection of parathyroid gland adenoma.
    Platz Batista da Silva N; Jung EM; Jung F; Schlitt HJ; Hornung M
    Clin Hemorheol Microcirc; 2018; 70(4):423-431. PubMed ID: 30347604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography.
    Moschouris H; Malagari K; Gkoutzios P; Kalokairinou M; Stamatiou K; Chatzimichail K; Kornezos I; Karagiannis E; Kiltenis M; Papadaki MG
    Med Ultrason; 2012 Jun; 14(2):87-94. PubMed ID: 22675707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative analysis of microcirculation blood perfusion in patients with hepatocellular carcinoma before and after transcatheter arterial chemoembolisation using contrast-enhanced ultrasound.
    Tian H; Wang Q
    Eur J Cancer; 2016 Nov; 68():82-89. PubMed ID: 27728840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contrast-Enhanced Ultrasound and Computed Tomography Assessment of Hepatocellular Carcinoma after Transcatheter Arterial Chemo-Embolization: A Systematic Review.
    Tai CJ; Huang MT; Wu CH; Tai CJ; Shi YC; Chang CC; Chang YJ; Kuo LJ; Wei PL; Chen RJ; Chiou HY
    J Gastrointestin Liver Dis; 2016 Dec; 25(4):499-507. PubMed ID: 27981306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.